Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Bullboard Posts
Comment by threefiftynineon Jun 04, 2020 8:30am
59 Views
Post# 31110402

RE:RE:---NO phase1 OR FUNDING =NO PP INVESTORS---

RE:RE:---NO phase1 OR FUNDING =NO PP INVESTORS---
I would imagine ISRAEL is where the bank account is. The head office here in TORONTO is only for Canadian tsx listing requirement. Getting back to the PP--Just doesn't make sense in all aspects of corporate public business. Virtually no overheads -$1.4 million in the chequing account with insider warrants still to be cashed in if necessary for cash flow , so as someone posted earlier it may make sense that insiders are loading up prior to a buyout (just a guess). If they get funding and PHASE1 kicks in and the share price goes up to new yearly highs then a buyout at much higher levels would make sense---This happens all the time in the corporate world where pockets are lined prior to a major catalyst---if that's the case well good luck to them---WINNER WINNER CHICKEN DINNER FOR ALL INVOLVED---the opposite doesn't bare thinking about. Keep your eyes on SEDI .
Bullboard Posts